Company Filing History:
Years Active: 2010-2013
Title: The Innovative Contributions of Reiner Laus in Cancer Therapy
Introduction
Reiner Laus, based in Saratoga, California, stands out as an inventive mind in the realm of cancer therapeutics. With a remarkable portfolio of four patents, he has significantly contributed to developing innovative therapies designed to combat prostate cancer and enhance treatment options for patients. His work exemplifies the intersection of science and practical application in the medical field.
Latest Patents
Among his latest inventions are groundbreaking approaches utilizing modified vaccinia Ankara (MVA) viruses. One notable patent focuses on the "Use of MVA to treat prostate cancer." This invention involves compositions, kits, and methods for cancer prophylaxis and therapy using recombinant MVA viruses that encode tumor-associated antigens, such as prostate-specific antigen (PSA) and prostatic acid phosphatase (PAP). The robust immune response induced by these viruses is pivotal, offering new avenues for treatment when administered in conjunction with taxanes.
Another significant innovation by Reiner Laus is a method for treating cancer using a recombinant MVA expressing HER-2. This patent outlines the development of treatments using recombinant MVA viruses encoding the HER-2 antigen, particularly when combined with taxane therapies. By leveraging these advancements, Laus aims to provide enhanced therapeutic strategies for cancer patients.
Career Highlights
Reiner Laus has garnered recognition in his field for his innovative thinking and contributions to cancer research. Working at Bn Immunotherapeutics, Inc., he has played a vital role in driving projects that aim at improving patient outcomes through groundbreaking cancer therapies. His commitment to research and development is reflected in his successful patent portfolio.
Collaborations
Throughout his career, Reiner Laus has collaborated with other prominent figures in the field, including Alain Delcayre and Stefanie Mandl. These partnerships have been instrumental in fostering innovation and advancing the development of effective cancer treatments. Sharing insights and expertise, Laus and his colleagues endeavor to push the boundaries of what is possible in medical science.
Conclusion
Reiner Laus emerges as a critical figure in the fight against cancer, demonstrating exceptional ingenuity through his innovative patents and collaborative ventures. His work at Bn Immunotherapeutics, Inc. not only showcases his commitment to enhancing therapeutic strategies but also reinforces the importance of innovation in improving patient care. As he continues to explore new frontiers in cancer treatment, the impact of his inventions may pave the way for groundbreaking advancements in oncology.